ImmuCell Corporation cash flow to debt ratio of 18.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ImmuCell Corporation's free cash flow has increased -1.24K% from $-107.82K last year to $1.22M, signaling increasing performance

ImmuCell Corporation's debt to equity ratio is 0.44, which means that the company's assets are healthy financed, signaling financial stability.

ImmuCell Corporation's debt has decreased relative to shareholder equity from 0.55 last year to 0.44 today, signaling strengthened financials

ImmuCell Corporation has a net debt to EBITDA ratio of 4.39x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

ImmuCell Corporation's interest coverage ratio of 5.41 indicates that earnings with good margin can cover interest payments on company debt

ImmuCell Corporation's profit margin has increased (-77.62%) in the last year from -8.14% to -1.82%, signaling increasing performance

ImmuCell Corporation's short-term assets of $16.94M exceed its short-term liabilities of $3.98M

ImmuCell Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ImmuCell Corporation's return on equity of -1.88%, is lower than 15.00%, indicating bad performance

ImmuCell Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ImmuCell Corporation had positive net income in only 0 out of 5 years, indicating unstable earnings

ImmuCell Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

ImmuCell Corporation has a free cash flow yield of 1.23%, which is below the 2.00% threshold, indicating limited cash return relative to market value

ImmuCell Corporation's yearly earnings has increased -51.78% since last year from $-2.16M to $-1.04M, signaling increasing performance

ImmuCell Corporation's yearly revenue has increased 4.34% since last year from $26.49M to $27.64M, signaling increasing performance

ROIC 5.97% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

ImmuCell Corporation's 3-year revenue CAGR of 14.19% is positive, indicating growing revenue over the past 3 years

ImmuCell Corporation had revenue growth in 3 out of 5 years, indicating consistent revenue performance

ImmuCell Corporation had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ImmuCell Corporation has insufficient data to evaluate this check.

ImmuCell Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ImmuCell Corporation is overvalued relative to its fair value price of 2.40 based on EBITDA multiple model

ImmuCell Corporation has an EV/EBITDA ratio of 50.76x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

ImmuCell Corporation is overvalued relative to its fair value price of -3.67 based on Earnings Fair Value model

ImmuCell Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ImmuCell Corporation has a price-to-book ratio of 3.41x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ImmuCell Corporation has a price-to-sales ratio of 3.32x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue